411 related articles for article (PubMed ID: 19917366)
21. Living Donor Preemptive Kidney Transplantation in Tuberous Sclerosis Complex Patient and the Role of Mammalian Target of Rapamycin Inhibitor: A Case Report.
Tarasewicz A; Dębska-Ślizień A; Rutkowska B; Szurowska E
Transplant Proc; 2020 Oct; 52(8):2520-2523. PubMed ID: 32448667
[TBL] [Abstract][Full Text] [Related]
22. Possible prevention of tuberous sclerosis complex lesions.
Kotulska K; Borkowska J; Jozwiak S
Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
[TBL] [Abstract][Full Text] [Related]
23. Nursing implications for the lifelong management of tuberous sclerosis complex.
Agricola K; Tudor C; Krueger D; Franz DN
J Neurosci Nurs; 2013 Aug; 45(4):226-42. PubMed ID: 23812052
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Mammalian Target of Rapamycin Inhibitor Use-Long-term Follow-up of First Tuberous Sclerosis Complex Patient Treated De Novo With Sirolimus After Kidney Transplantation: A Case Report.
Tarasewicz A; Dębska-Ślizień A; Rutkowska B; Szurowska E; Matuszewski M
Transplant Proc; 2018; 50(6):1904-1909. PubMed ID: 30056926
[TBL] [Abstract][Full Text] [Related]
25. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex.
Pressey JG; Wright JM; Geller JI; Joseph DB; Pressey CS; Kelly DR
Pediatr Blood Cancer; 2010 Jul; 54(7):1035-7. PubMed ID: 20108343
[TBL] [Abstract][Full Text] [Related]
26. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex.
Franz DN; Leonard J; Tudor C; Chuck G; Care M; Sethuraman G; Dinopoulos A; Thomas G; Crone KR
Ann Neurol; 2006 Mar; 59(3):490-8. PubMed ID: 16453317
[TBL] [Abstract][Full Text] [Related]
27. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
Boggarapu S; Roberds SL; Nakagawa J; Beresford E
Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
[TBL] [Abstract][Full Text] [Related]
28. The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27.
Rosner M; Freilinger A; Hengstschläger M
Mutat Res; 2006 Sep; 613(1):10-6. PubMed ID: 16713332
[TBL] [Abstract][Full Text] [Related]
29. Management of epilepsy in tuberous sclerosis complex.
Curatolo P; D'Argenzio L; Cerminara C; Bombardieri R
Expert Rev Neurother; 2008 Mar; 8(3):457-67. PubMed ID: 18345974
[TBL] [Abstract][Full Text] [Related]
30. Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex.
Al-Saleem T; Wessner LL; Scheithauer BW; Patterson K; Roach ES; Dreyer SJ; Fujikawa K; Bjornsson J; Bernstein J; Henske EP
Cancer; 1998 Nov; 83(10):2208-16. PubMed ID: 9827727
[TBL] [Abstract][Full Text] [Related]
31. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin.
El-Hashemite N; Walker V; Zhang H; Kwiatkowski DJ
Cancer Res; 2003 Sep; 63(17):5173-7. PubMed ID: 14500340
[TBL] [Abstract][Full Text] [Related]
32. Mutational analysis of TSC1 and TSC2 in Korean patients with tuberous sclerosis complex.
Choi JE; Chae JH; Hwang YS; Kim KJ
Brain Dev; 2006 Aug; 28(7):440-6. PubMed ID: 16554133
[TBL] [Abstract][Full Text] [Related]
33. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
34. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
35. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
36. Monotherapy rapamycin in renal transplant recipients with lymphoma successfully treated with rituximab.
Alexandru S; Gonzalez E; Grande C; Hernandez A; Morales E; Praga M; Andres A; Morales JM
Transplant Proc; 2009; 41(6):2435-7. PubMed ID: 19715944
[TBL] [Abstract][Full Text] [Related]
37. Developing multiple lung nodules in a renal transplant recipient with tuberous sclerosis who had undergone bilateral nephrectomy due to renal cell carcinomas.
Saito M; Yuasa T; Satoh S; Nanjo H; Tsuchiya N; Habuchi T
Int J Urol; 2008 Mar; 15(3):257-8. PubMed ID: 18304223
[TBL] [Abstract][Full Text] [Related]
38. Tuberous sclerosis in a 19-week fetus: immunohistochemical and molecular study of hamartin and tuberin.
Wei J; Li P; Chiriboga L; Mizuguchi M; Yee H; Miller DC; Greco MA
Pediatr Dev Pathol; 2002; 5(5):448-64. PubMed ID: 12202993
[TBL] [Abstract][Full Text] [Related]
39. Emerging treatments in the management of tuberous sclerosis complex.
Kohrman MH
Pediatr Neurol; 2012 May; 46(5):267-75. PubMed ID: 22520346
[TBL] [Abstract][Full Text] [Related]
40. A patient with TSC1 germline mutation whose clinical phenotype was limited to lymphangioleiomyomatosis.
Sato T; Seyama K; Kumasaka T; Fujii H; Setoguchi Y; Shirai T; Tomino Y; Hino O; Fukuchi Y
J Intern Med; 2004 Aug; 256(2):166-73. PubMed ID: 15257730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
